Trial Profile

A Clinical Study of SCH 54031 [peginterferon alfa 2b] as Monotherapy in IFN[Interferon]-Treated Patients With Chronic Hepatitis C.

Status: Discontinued

Phase of Trial: Phase III

Latest Information Update: 09 May 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Peginterferon alfa-2b (Primary) ; Glycyrrhizin
Indications Hepatic fibrosis; Hepatitis C
Focus Therapeutic Use
Sponsors Schering-Plough

Most Recent Events

27 Mar 2012 Planned end date changed from 1 Jul 2011 to 1 Feb 2011 as reported by ClinicalTrials.gov.
27 Mar 2012 Status changed from completed to discontinued as reported by ClinicalTrials.gov.
05 Mar 2012 Primary endpoint identified as Assessment-scale-scores as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com